Insight Molecular Diagnostics (IMDX) Operating Leases (2019 - 2023)

Insight Molecular Diagnostics has disclosed Operating Leases across 5 years of filings, most recently posting $2.1 million for Q4 2023.

• Operating Leases for Q4 2023 came in at $2.1 million, down 22.98% year-over-year; the trailing twelve-month figure through Dec 2023 was $2.1 million (down 22.98% YoY), and the FY2023 annual result was $2.1 million, down 22.98% from the prior year.
• Operating Leases came in at $2.1 million for Q4 2023 at Insight Molecular Diagnostics, down from $2.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $4.3 million in Q4 2020 to a low of $2.1 million in Q4 2023.
• The 5-year median for Operating Leases is $3.2 million (2022), against an average of $3.2 million.
• Across the five-year window, Operating Leases surged 61.14% in 2020 and dropped 23.33% in 2023, its largest moves.
• Insight Molecular Diagnostics' Operating Leases stood at $2.7 million in 2019, then surged by 61.14% to $4.3 million in 2020, then retreated by 17.79% to $3.5 million in 2021, then fell by 23.02% to $2.7 million in 2022, then declined by 22.98% to $2.1 million in 2023.
• The last three Operating Leases figures came in at $2.1 million (Q4 2023), $2.6 million (Q1 2023), and $2.7 million (Q4 2022), per Business Quant data.